

February 1, 2023
Nobelpharma Co., Ltd.

**『NOBELZIN® Granules 5%』 Launched
for Treatment of Wilson's Disease (copper absorption inhibitor) and Hypozincemia**

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Managing Director & CEO: Jin Shiomura) announced today that the company has launched NOBELZIN® Granules 5% for Wilson's disease (copper absorption inhibitor) and hypozincemia.

This new formulation, which was approved on January 22, 2021, had been developed in the best interest of younger children requiring detailed dose adjustment and elderly patients having swallowing difficulties. Despite the effort to launch the product within three months after the NHI price listing on May 26 of the same year, the launch was compelled to be postponed from the viewpoint of securing stable supply.

We sincerely apologize for the delay and the consequent inconvenience caused to the patients and healthcare providers.

With this launch, we hope that NOBELZIN® Granules 5% will become a new option for pediatric patients at early age and elderly patients with swallowing problems.

We are determined to continue contributing to society by providing critical but neglected pharmaceuticals and medical devices.

[Contact for Inquiries]

Noboru Kudo, Head of Communications

Nobelpharma Co., Ltd.

1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033

Tel: 03-6670-3800